"Evaluation of C-Reactive Protein Before and On-Treatment as a Predictor of Benefit of Atorvastatin"
JACC Aug 2013
http://content.onlinejacc.org/article.aspx?articleid=1727135
"Conclusions  In these primary prevention patients, although baseline CRP independently predicted CV event risk, the achieved CRP level on while statin therapy did not predict CV events, either alone or in combination with LDL-C."